Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 21, 2024
Finance
Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M
Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
BioCentury | Nov 1, 2018
Emerging Company Profile
Secarna’s next-gen oligos
Why Secarna is developing antisense oligonucleotides for immuno-oncology
BioCentury | Jan 26, 2017
Strategy
Deep roots
Geisinger and Regeneron mine the heartland for targets and precision therapies
BioCentury | Feb 11, 2013
Emerging Company Profile
GeneCentric: Cancer sign-off
GeneCentric is developing cancer diagnostics based on gene signatures
BioCentury | Dec 3, 2012
Emerging Company Profile
Lipigon: LPL protectorate
Lipigon taking new approach to lipoprotein lipase to prevent atherosclerosis
Items per page:
1 - 10 of 13